Liminatus Pharma, Inc.
LIMN
$1.28
-$0.03-2.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 06/30/2024 | |||
|---|---|---|---|---|---|
| Net Income | -71,233.33% | 99.87% | -1,357,350.00% | ||
| Total Depreciation and Amortization | -- | -- | -- | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | -- | -- | -- | ||
| Change in Net Operating Assets | -2,497,833.33% | -99.66% | 805,250.00% | ||
| Cash from Operations | -- | 100.00% | -- | ||
| Capital Expenditure | -- | -- | -- | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -- | -- | ||
| Cash from Investing | -- | -- | -114.29% | ||
| Total Debt Issued | -- | -- | -- | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | -- | -- | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -- | -- | -- | ||
| Cash from Financing | -- | -- | 89.35% | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | -- | -- | 1.89% | ||